Role of Cholinergic Signaling in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 139 of the 141 references it cites were found in a registry or an index.
Abstract
Acetylcholine, a neurotransmitter secreted by cholinergic neurons, is involved in signal transduction related to memory and learning ability. Alzheimer’s disease (AD), a progressive and commonly diagnosed neurodegenerative disease, is characterized by memory and cognitive decline and behavioral disorders. The pathogenesis of AD is complex and remains unclear, being affected by various factors. The cholinergic hypothesis is the earliest theory about the pathogenesis of AD. Cholinergic atrophy and cognitive decline are accelerated in age-related neurodegenerative diseases such as AD. In addition, abnormal central cholinergic changes can also induce abnormal phosphorylation of ttau protein, nerve cell inflammation, cell apoptosis, and other pathological phenomena, but the exact mechanism of action is still unclear. Due to the complex and unclear pathogenesis, effective methods to prevent and treat AD are unavailable, and research to explore novel therapeutic drugs is various and active in the world. This review summaries the role of cholinergic signaling and the correlation between the cholinergic signaling pathway with other risk factors in AD and provides the latest research about the efficient therapeutic drugs and treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second-generation AChEIs, including donepezil (4), rivastigmine (5), galantamine (6), are more selective. They exhibited fewer side effects or improved pharmacokinetic profiles, establishing them as first-line drugs for AD.98,400”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is a progressive neurodegenerative disorder and the leading cause of dementia among older adults, characterized by a gradual decline in cognitive function, memory loss, and behavioral changes, ultimately leading to complete dependence on caregivers [7].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these, neurons of the nucleus basalis of Meynert (NBM) are particularly vulnerable, and their degeneration leads to profound reductions in choline acetyltransferase (ChAT) activity within projection areas such as the cerebral cortex and hippocampus, regions essential for learning, memory, and attention [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This hypothesis suggests that a reduction in the synthesis and release of ACh impairs its physiological functions, which are critical for learning, memory, and other cognitive processes.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“The cholinergic hypothesis, one of the earliest and most influential theories of AD, proposed that the characteristic cognitive deficits of the disorder arise primarily from degeneration of cholinergic neurons in the basal forebrain [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Hafez, H. S., Ghareeb, D. A., Saleh, S. R., Abady, M. M., Demellawy, M. E., Hussien, H. M., & Abdel-Monem, N. M. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4690-x · Cited by 85
RetractedSemwal, B. C., & Garabadu, D. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08615-1 · Cited by 9 · cited 2×
“Aβ can induce mitochondrial toxicity in the brain, resulting in cognitive dysfunction [5].”
BackgroundRetractedNEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311 · cited 1×
“According to clinical data in recent years, the brains of patients with AD show severe neurodegeneration and reduction of cholinergic neurons and a severe deficiency of Ach; acetylcholine transferase activity is significantly decreased, which further illustrates the damage to the cholinergic system in patients with AD…”
BackgroundEfficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Román, G. C., Jackson, R. E., Gadhia, R., Román, A. N., & Reis, J. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.08.005 · Cited by 421
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease
Osborn, L. M., Kamphuis, W., Wadman, W. J., & Hol, E. M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.001 · Cited by 312 · cited 1×
“AD is a major cause of dementia which is a common disease among the elderly, starting with an irreversible decline in episodic memory and then a more general decline in overall cognitive ability [2,3].”
BackgroundLiu, Y., Zhang, Y., Zheng, X., Fang, T., Yang, X., Luo, X., Guo, A., Newell, K. A., Huang, X.-F., & Yu, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1141-5 · Cited by 285 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
BackgroundLuo, H., Xiang, Y., Qu, X., Liu, H., Liu, C., Li, G., Han, L., & Qin, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00395 · Cited by 264 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
Background
Research works printed but not linked: 1
- Yu, 2019, Protective roles of isoastilbin against Alzheimer’s disease via Nrf2mediated antioxidation and antiapoptosis, Int. J. Mol. Med., 43, 1406
Cited by
Items 401–500 of 1,000
Cardinali, C. A. E. F., Martins, Y. A., de Moraes, R. C. M., Costa, A. P., Alencar, M. B., Silber, A. M., & Torrão, A. D. S. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00113 · Cited by 5
Zhang, T., Zhou, L., Li, R., Zhao, H., Cui, Y., Wang, L., & Xiao, H. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135680 · Cited by 5
Ghaderi, S., Fatehi, F., Kalra, S., Okhovat, A. A., Nafissi, S., Mohammadi, S., & Batouli, S. A. H. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111125 · Cited by 5
Petkova-Kirova, P. S., Anastassova, N., Minchev, B., Uzunova, D. N., Grigorova, V., Tsvetanova, E. R., Georgieva, A. P., Alexandrova, A., Stefanova, M. O., Yancheva, D. Y., et al. (2024) · Molecules · doi:10.3390/molecules29235711 · Cited by 5
“…cholinergic system, enhanced oxidative stress and impaired antioxidants defense, neuroinflammation, unfavorable changes in the monoaminergic neurotransmitter systems, mitochondrial alterations, apoptosis, and compromised BDNF signaling [34], pathological changes accompanying AD as well [35–43].”
Seo, J., Kim, J., Ko, Y., Lee, B., Hur, K., Jung, Y. H., Park, H., Lee, S., & Jang, C. (2025) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.110 · Cited by 5
Wang, W., Sun, Y., Cao, R., Luo, W., Beng, S., Zhang, J., Wang, X., & Peng, C. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118060 · Cited by 5
Tunçel, Ş. T., Günal, Ş. E., Demir, İ., Baysal, İ., Erdem, S. S., Telli, G., Uçar, G., Doğan, İ., & Kelekçi, N. G. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117986 · Cited by 5
Tang, C., Yang, J., Lei, X., Zhang, M., Chen, Y., Peng, X., & He, D. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70605 · Cited by 5
Hamdi, E., Hidouri, S., Muñiz‐González, A., Kechnebbou, M., & Amara, S. (2025) · Nano TransMed · doi:10.1016/j.ntm.2025.100074 · Cited by 5
Acetylcholine - Recent Advances and New Perspectives
Heinbockel, T. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.106304 · Cited by 5
Abdelli, A., Ouni, S., M’rabet, H., Efrit, M. L., & Prim, D. (2023) · Chemistry Africa · doi:10.1007/s42250-023-00783-4 · Cited by 5
Sarfraz, M., Ibrahim, M. K., Ejaz, S. A., Attaullah, H. M., Aziz, M., Arafat, M., Shamim, T., Elhadi, M., Ruby, T., & Mahmood, H. K. (2024) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04815-0 · Cited by 5
“These two forms are encoded by two different genes, and their tissue allocation systems and substrate specificities are completely different from one another [14].”
Khabiya, R., Karati, D., Dwivedi, S., Dwivedi, A., & Mukherjee, S. (2024) · Brain Disorders · doi:10.1016/j.dscb.2024.100125 · Cited by 5
Akinrinde, A. S., Adeoye, B. O., Samuel, E. S., & Mustapha, O. (2024) · Biological Trace Element Research · doi:10.1007/s12011-024-04258-6 · Cited by 5
Taheri, M., Mehr, M. A., & Ghafouri, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-80102-0 · Cited by 5
Mukilan, M. (2024) · Research Journal of Biotechnology · doi:10.25303/201rjbt055068 · Cited by 5
Ullah, I., Zhang, C., Shao, Y., Shen, J., & Zhu, H. (2025) · Dyes and Pigments · doi:10.1016/j.dyepig.2025.112636 · Cited by 5
Edo, G. I., Mafe, A. N., Akpoghelie, P. O., the Department of Veterans Affairs Cooperative Study Group o, Umelo, E. C., Yousif, E., Isoje, E. F., Igbuku, U. A., Opiti, R. A., Madueke, C. J., et al. (2025) · Phytomedicine Plus · doi:10.1016/j.phyplu.2025.100754 · Cited by 5
Rustage, K., Rai, N., Sinha, S. K., Goyal, J., Chouhan, P., Baniya, B., Dubey, D., Singhal, R., Malani, P., Pareek, A., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04910-9 · Cited by 5
Kermaninia, S., Mohammadi‐Khanaposhtani, M., Şenol, H., Mohammadilar, F. S. K., Dastyafteh, N., Moradkhani, F., Saeedi, S., Larijani, B. A., Dadgar, A., Aktaş, A., et al. (2025) · RSC Advances · doi:10.1039/d5ra03877d · Cited by 6
Rodriguez, J. J., Gardenal, E., Zallo, F., Cabot, J., & Busquets, X. (2024) · Acta Histochemica · doi:10.1016/j.acthis.2024.152194 · Cited by 4
Li, Y., Go, M. A., Zhang, H., Aleksynas, R., Kim, J., Gao, M., Prado, S. V., Sastre, M., & Schultz, S. R. (2026) · Advanced Science · doi:10.1002/advs.77419 · Cited by 4
Lee, S.-S., Ko, D.-H., Kim, S.-Y., Lee, G.-Y., Han, S. Y., Park, J.-Y., Park, M. S., Kim, H., Kim, Y.-E., & Yoo, Y. C. (2025) · Cells · doi:10.3390/cells14130977 · Cited by 4
“Significant decreases in acetylcholine activity are commonly observed in neurodegenerative diseases, including Alzheimer’s disease [47].”
Douae, B., Bikri, S., Aboubi, M. E., Yassif, F.-Z., & Aboussaleh, Y. (2025) · Frontiers in Toxicology · doi:10.3389/ftox.2025.1610720 · Cited by 4
Zhang, Y., Zhang, Y., Liu, C., Liang, J., Nong, Y., Chen, M., Sun, R., Ito, Y., & Li, S. (2025) · Industrial Crops and Products · doi:10.1016/j.indcrop.2025.121654 · Cited by 4
Assessment of Biological Activity of Low Molecular Weight 1,4-Benzoquinone Derivatives
Bartolić, M., Matošević, A., Maraković, N., Novaković, I., Sladić, D. M., Žunec, S., Opsenica, D., & Bosak, A. (2025) · Biomolecules · doi:10.3390/biom15081162 · Cited by 4
Gautam, A. S., Akhtar, M. Z., Lasure, V., Kumari, N., Pandey, S. K., Dey, M., & Singh, R. K. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10246-x · Cited by 4
“It has been established that the level of Ach is found be decreased during AD, and the corresponding impairment in the cholinergic system manifests dementia in AD patients (Chen et al. 2022 ).”
Afolayan, O. O., Nwaogu, V., Idowu, O. K., & Dosumu, O. O. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-05093-5 · Cited by 4
“Moreover, the increased AChE activity is linked to cholinergic neuronal loss in AD flies, which appears to impair locomotor function [44].”
Six-membered N-heterocyclic alkaloids as ChE inhibitors in alzheimer’s disease treatment
Yadav, P., Dabas, A., & Singh, R. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01740-5 · Cited by 4
“According to the cholinergic hypothesis, the acetylcho - line neurotransmitter, present in the pre-synaptic nerve ter - minal that is involved in many cognitive functions, such as learning and memory, declines in AD (Chen et al. 2022 ).”
Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer’s Disease
Ward, K., Cole, M. H., Griffiths, L. R., Sutherland, H. G. E., Winberg, P. C., Meyer, B. J., & Fernandez, F. (2025) · Molecules · doi:10.3390/molecules30224456 · Cited by 4
Causal Associations between Sleep Apnea and Dementia: A Two-Sample Mendelian Randomization Study
Zhao, L., Xia, L., Xu, Y., & Zhang, Y. (2025) · Archives of Medical Science · doi:10.5114/aoms/214094 · Cited by 4
Salter, D., Gupta, S. V. B., Sairam, B., Gupta, A. K., & Maurya, R. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1695341 · Cited by 4
“Elevated levels of AChE result in depleted levels of acetylcholine at the synaptic cleft, a phenomenon implicated in the pathophysiology of memory loss observed in neurodegenerative diseases (65).”
Barani, M., Zargari, F., Mirinejad, S., Madani, F., Hajinezhad, M. R., & Sargazi, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-32528-3 · Cited by 4
Treder, N., & Bączek, T. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121593 · Cited by 4
“One of the earliest is the progressive loss of cholinergic neurons in the basal forebrain, leading to reduced acetylcholine levels in the cortex and hippocampus—regions critical for memory and cognition [25,26].”
Targeting muscarinic receptors for treating schizophrenia
Paul, S. M., & Yohn, S. E. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00839 · Cited by 4
“In these conditions, cholinergic signaling is disrupted either because the neurons that release ACh degenerate or because the receptors that respond to it function abnormally [23].”
Dragomir, A.-F., Stoleru, S., Zugravu, A., Poenaru, E., Dumitrescu, M. C., Barbu, A. C., Fratea, S., Stoleru, C. M., Coman, O. A., & Fulga, I. (2026) · Biomedicines · doi:10.3390/biomedicines14040938 · Cited by 4
“Degeneration of basal forebrain cholinergic neurons reduces acetylcholine release in cortical and hippocampal circuits, thereby diminishing muscarinic receptor activation and compromising synaptic communication within networks supporting learning and memory [5,6].”
Khattab, N. A., El-Kadem, A. H., Goda, A. E., El‐Mahdy, N. A., & El‐Shitany, N. A. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115814 · Cited by 4
Genomic and proteomic conversion of brain ischemia to Alzheimer’s disease
Pluta, R. M., & Ułamek-Kozioł, M. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1804251 · Cited by 4
“On the other hand, impaired cholinergic activity may also affect mitochondrial behavior by limiting the control of their function by acetylcholine (Chen Y. et al., 2022; Chen Z. R. et al., 2022).”
Acetylcholine in Brain–Body Communication: Biological Mechanisms and Physiological Roles
Gao, Y., Zhou, T., Lai, X., & Fei, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114686 · Cited by 4
“Central cholinergic circuits regulate signaling throughout the cerebral cortex and support higher-order cognitive processes [69].”
Yıldırım, C., Çevik, S., Bal, R., Kaplan, D. S., Yılmaz, Ş. G., Ulusal, H., & Bekerecioğlu, S. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05947-0 · Cited by 4
Yılmaz, F., Menteşe, E., Eyüpoğlu, O. E., Kahveci, B., & Emirik, M. (2026) · Drug Development Research · doi:10.1002/ddr.70369 · Cited by 4
Zhao, K., Dai, S., Zhang, Y., Liu, G., Gu, P., Lin, C., Thompson, P. M., Leow, A., Huang, H., He, L., et al. (2026) · Frontiers in Radiology · doi:10.3389/fradi.2026.1912277 · Cited by 4
“Meanwhile, the model highlights a subset of genes — such as RBFOX1 , CNTNAP2 , and CHAT — that participate in neuronal connectivity, synaptic function, and cholinergic signaling, domains increasingly understood to deteriorate early in AD (89).”
Mast, N., Li, Y., & Pikuleva, I. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042242 · Cited by 4
“Therefore, this neurotransmitter was quantified in the present work as a difference between the content of total (free choline plus Ach after the hydrolysis of the acetyl group) and free choline (Figure 5).”
BackgroundTalwar, A., Chatterjee, S., Sherer, J. T., Abughosh, S., Johnson, M. L., & Aparasu, R. R. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01103-2 · Cited by 4
“The long-term cholinergic blockade increases the beta-amyloid peptide in the cortex, hippocampus, and amygdala, thus negatively affecting the condition of this patient population [16].”
Seruji, N. M. U., Jong, V. Y. M., Karunakaran, T., Zamakshshari, N. H., Mah, S. H., Gunter, N. V., Lizazman, M. A., & Masayoshi, A. (2024) · Phytochemistry Letters · doi:10.1016/j.phytol.2024.08.007 · Cited by 4
Nurinsani, E. Y. Y., Andrianto, D., & Safithri, M. (2024) · BIO Web of Conferences · doi:10.1051/bioconf/202412302009 · Cited by 4
Yadav, E., Mandal, A. K., Sah, A. K., Poudel, S., Pathak, P., Khalilullah, H., Jaremko, M., Emwas, A.-H. M., Yadav, P. S., & Verma, A. (2024) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273298025240905130205 · Cited by 4
Kumar, S., Mitra, R., & Ayyannan, S. R. (2024) · Molecular Diversity · doi:10.1007/s11030-024-11031-3 · Cited by 4
Mohamed, D. A., Mohamed, R. S., Fouda, K. A., & Mabrok, H. B. (2025) · PubMed Central · doi:10.22038/ijbms.2024.79960.17320 · Cited by 4
Martínez-Orozco, H., Bencomo-Martínez, A., Maya-Arteaga, J. P., Anda, P. F. R.-D., Sanabria-Romero, F., Casas, Z. G. M., Vargas-Rodríguez, I., Hernández‐Puga, G., Sablón-Carrazana, M., del Valle, R. M.-S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031301 · Cited by 4
“The levels of ACh are diminished in the brains of patients diagnosed with AD [7,41,42].”
Sohn, E., Kim, B., Kim, Y. J., Kim, J., & Jeong, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-88152-8 · Cited by 4
“The cholinergic system plays an essential role in memory formation 2,3 .”
Baidya, A. T. K., Dante, D., Das, B., Wang, L., Darreh‐Shori, T., & Kumar, R. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177638 · Cited by 4
Memory-Enhancing Effects of Daidzin, Possibly Through Dopaminergic and AChEergic Dependent Pathways
Islam, M. T., Prottay, A. A. S., Bhuia, M. S., Akbor, M. S., Chowdhury, R., Ansari, S. A., Ansari, I. A., Islam, M. A., Tahim, C. M., & Coutinho, H. D. M. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.04.024 · Cited by 4
Fluorescent method for acetylcholinesterase activity detection and its inhibitors screening
Xiao, M., Tang, Y., Liu, A., Zhang, X., Wang, C., & Wei, W. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.114147 · Cited by 4
Tunç, T., Kılınç, N., Demirel, N., & Alım, Z. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202500974 · Cited by 4
Twarowski, B., Piątkowska‐Chmiel, I., & Herbet, M. (2025) · Current Neuropharmacology · doi:10.2174/011570159x389970250727031306 · Cited by 4
“Cholinergic changes mainly include atrophy of the cortex and hippocampus, combined with loss of synaptic connections [50].”
Promyo, K., Cho, A.-R., Song, D., Sharma, D., Jaiswal, L., Sangpreecha, N., Cho, J., Kang, S., & Ham, K. (2025) · Applied Biological Chemistry · doi:10.1186/s13765-025-01054-1 · Cited by 4
Graf, C., Wagener, I., Grikscheit, K., Hoehl, S., Berger, A., Wetzstein, N., Dietz, J., Dultz, G., Michael, F. A., Filmann, N., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093162 · Cited by 4
“Involvement of the limbic cholinergic system in turn has been observed in olfactory processing in animal studies and in Alzheimer’s disease and thus may also play an important role in SARS-CoV-2 mediated OD [49].”
BackgroundThe Overview of Drugs Used in Alzheimer’s Disease and Their Molecular Targets
Vishwas, S., Gulati, M., Babu, M. R., Awasthi, A., Kumar, R., Khursheed, R., Corrie, L., Chaitanya, M., Gupta, G., Devkota, H. P., et al. (2023) · Springer eBooks · doi:10.1007/978-981-99-2657-2_15 · Cited by 4
Jain, S. K., Margret, J. J., & Lally, M. M. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.10.399 · Cited by 4
Atrophy of the cholinergic regions advances from early to late mild cognitive impairment
Lai, Y.-L. L., Hsu, F., Yeh, S.-Y., Kuo, Y.-T., Lin, H.-H., Lin, Y., Kuo, L., Chen, C., Liu, H.-S., & Initiative, A. D. N. (2024) · Neuroradiology · doi:10.1007/s00234-024-03290-6 · Cited by 4
The role of glutamic acid-modified silica nanoparticles in promoting brain health
Hamdi, E., Hidouri, S., Muñiz‐González, A., Marcos, A., Venero, C., Amara, S., & Landoulsi, A. (2024) · Advances in Redox Research · doi:10.1016/j.arres.2024.100095 · Cited by 4
Coptisine reverses Alzheimer’s disease by targeting cholinergic and amyloidogenic pathways
Roy, A., Roy, R., Meena, B. S., Kumar, D., Bhattacharya, P., Gahatraj, I., Chhetry, S., & Borah, A. (2024) · Medical Hypotheses · doi:10.1016/j.mehy.2024.111407 · Cited by 4
Pašti, T. D. L., Anićijević, V. J., Karkalić, R., Baljozović, M., Babić, B., & Pašti, I. A. (2024) · C – Journal of Carbon Research · doi:10.3390/c10020056 · Cited by 4
“Accordingly, the inhibition of AChE results in the accumulation of C 2024 , 10 , 56 2 of 20 acetylcholine, leading to heightened stimulation of nicotinic and muscarinic receptors and, consequently, disruption of neurotransmission [11,12].”
BackgroundAbdulkadir, T. S., & Ayo, J. O. (2024) · Comparative Clinical Pathology · doi:10.1007/s00580-024-03603-4 · Cited by 4
Azhir, M., Gazmeh, S., Elyasi, L., Jahanshahi, M., & Bazrafshan, B. (2023) · Yādgār. · doi:10.61186/jcbr.7.4.15 · Cited by 4
“This progressive disease starts with an irreversible decline in episodic memory and in the overall cognitive ability of the patients, which deteriorates and finally results in death (4-8).”
Pandey, K., Srivastava, P., Pandey, S. K., Johari, S., Bhatnagar, P., Sonane, M., & Mishra, A. (2024) · Current Molecular Medicine · doi:10.2174/0115665240334785240913071442 · Cited by 4
Song, X., Wang, X., Gao, Y., Xu, G., Yan, X., Chen, Z., & Song, G. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266322320240911194626 · Cited by 4
Self-citationHamed, G. M., Morsy, W. E., Elnahrawy, E. A. B., & Hamid, M. S. A.-E. (2024) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-024-00362-0 · Cited by 4
“In the same context, Chen et al. [39] high-lighted the crucial role of hippocampal cholinergic system in regulating neurogenesis, neuronal differentiation, synaptic plasticity, and mediating neuroprotection through their anti-inflammatory and antioxidant effects.”
Thongwong, P., Wattanathorn, J., & Thukham-mee, W. (2024) · Nutrients · doi:10.3390/nu16234144 · Cited by 4
Haskologlu, I. C., Erdağ, E., Uludağ, M. O., & Abacıoğlu, N. (2024) · Chronobiology in Medicine · doi:10.33069/cim.2024.0033 · Cited by 4
“Interestingly, the brains of patients with AD exhibit higher levels of BChE activity, even though BChE is generally less selective and breaks down acetylcholine (ACh) more slowly than AChE, particularly in the later stages of the disease [2].”
Lee, H., Chater, J. M., Heinitz, C. C., & Wang, Y. (2025) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.14176 · Cited by 4
Mandragora autumnalis Distribution, Phytochemical Characteristics, and Pharmacological Bioactivities
Albahri, G., Badran, A., Baki, Z. A., Alamé, M., Hijazi, A., Daou, A., Mesmar, J. E., & Baydoun, E. (2025) · Pharmaceuticals · doi:10.3390/ph18030328 · Cited by 4
“This rapidly growing field of study (nanoscience and nanotechnology) deals with systems, devices, and structures with unique characteristics and capabilities because of the way their atoms are arranged on the 1–100 nm scale [87].”
Li, L., Zhao, P., Yang, C., Yin, Q., Wang, N., Liu, Y., & Li, Y. (2025) · Molecules · doi:10.3390/molecules30102093 · Cited by 4
“Consequently, therapeutic strategies targeting the cholinergic system have emerged as a vital therapeutic target for AD [9].”
Kumbhare, D., Rajagopal, M., Toms, J., Freelin, A. H., Weistroffer, G. R., McComb, N., Karnam, S., Azghadi, A., Murnane, K. S., Baron, M. S., et al. (2025) · Behavioral Neuroscience · doi:10.1037/bne0000625 · Cited by 4
Brinza, I., Boiangiu, R. Ş., Todirașcu-Ciornea, E., Hriţcu, L., & Dumitru, G. (2025) · Molecules · doi:10.3390/molecules30132858 · Cited by 4
“…degeneration, while transcriptional dysregulation of key regulatory factors such as nuclear factor erythroid 2-related factor 2 (Nrf2), cAMP response element-binding pro-Molecules tein (CREB), and brain-derived neurotrophic factor (BDNF) impairs neuronal resilience and synaptic plasticity [4–6].”
Godela, A., Rogacz, D., Pawłowska, B., & Biczak, R. (2025) · Molecules · doi:10.3390/molecules30153158 · Cited by 4
“AD is a multifactorial, progressive neurodegenerative disorder that arises from complex interactions among genetic, environmental, and lifestyle-related factors [2,3].”
Neuroprotective effects of ivermectin on Alzheimer’s model induced by streptozotocin in rats
Farajpour, N., & Soraya, H. (2025) · Neurodegenerative Disease Management · doi:10.1080/17582024.2025.2554374 · Cited by 4
Unveiling the Latest Biological Insights of Indole and its Derivatives: A Compact Review
Hiyashree Sharmah, L. A. A., Ahmed, L. A., Tapadar, S. B., Alam, M. K., Hoque, N., Mistry, K., Borah, L., Gogoi, H., & Hussain, I. (2024) · Journal of chemical health risks · Cited by 4
Ostovan, V. R., Baberi, N., Farokhi, M. R., Moezi, L., Pirsalami, F., SoukhakLari, R., & Moosavi, M. (2023) · Neurological Research · doi:10.1080/01616412.2023.2257417 · Cited by 4
“Acetylcholine (ACh) is a key neurotransmitter which is suggested to be involved in AD [2].”
BackgroundTobuse, A. J., Law, C. S. W., Thy, C. K., James, J. J., Chee, C. F., & Yeong, K. Y. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03179-8 · Cited by 4
“The cognitive decline in AD cases has been identi fi ed to be associated with dysfunction of the cholinergic system in patients [5 – 7].”
Vegan and Vegetarian Soups Are Excellent Sources of Cholinesterase Inhibitors
Gajowniczek-Ałasa, D., Baranowska‐Wójcik, E., & Szwajgier, D. (2024) · Nutrients · doi:10.3390/nu16132025 · Cited by 4
“The cholinesterase theory suggests that inhibiting both enzymes could potentially increase ACh levels, thereby enhancing neurotransmission and cognitive function in individuals with AD [2].”
BackgroundCholinergic Transporters Serve as Potential Targets in Alzheimer’s Disease
Bist, R., & Bhatt, D. K. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230505155302 · Cited by 4
She, X. (2025) · arXiv (Cornell University) · doi:10.48550/arxiv.2512.10981 · Cited by 4
Koca, M. (2022) · Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi · doi:10.21597/jist.1117484 · Cited by 3
Kumar, S., Mitra, R., & Ayyannan, S. R. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03304-1 · Cited by 3
“High level of AChE has been observed in the AD patients along with decreased level of ACh [9].”
Zilani, M. N. H., Nahar, N., Shome, A., Tareq, M. M. I., Biswas, P., Bibi, S., Alshammari, A., Albekairi, N. A., Alqahtani, H. M., & Hasan, M. N. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202401257 · Cited by 4
Cho, G., Kelly, K., Toyonaga, T., Carson, R. E., Miner, B., Gelernter, J. E., Varma, P., van Dyck, C. H., Mecca, A. P., & O’Dell, R. S. (2026) · The American Journal of Geriatric Psychiatry Open Science Education and Practice · doi:10.1016/j.osep.2026.04.002 · Cited by 3
Meo, M. C. D., Napoletano, P., Marco, A. D., Bianchi, A. R., Nisco, M. D., Cardinale, G., & Palatucci, D. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e43603 · Cited by 3
Jiang, B., Guan, J., Lv, Y., Yang, C., Yang, M., Shen, X., Xu, B., Wang, Q., Qin, Y., & Wu, L. J. (2025) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2025.138511 · Cited by 3
Taibi, M., Elbouzidi, A., Baraich, A., Haddou, M., Loukili, E. H., Bellaouchi, R., Mothana, R. A., Alanzi, A. R., Saalaoui, E., Firdaous, L., et al. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202403372 · Cited by 3
Role of GSK-3 Inhibition in Alzheimer’s Disease Therapy
Algazzawi, H., Abujamai, J. Z., Alshanberi, A. M., Satar, R., & Ansari, S. A. (2025) · Current Alzheimer Research · doi:10.2174/0115672050400781250904082943 · Cited by 3
Jastrzębski, M. K., Wójcik, P., Mudgal, A., Woźniak, S., Targowska‐Duda, K. M., Wronikowska‐Denysiuk, O., Michalak, A., Jeleniewicz, W., Karcz, T. P., Raczek, J., et al. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70232 · Cited by 3
Tok, F., Baltaş, N., Abas, B. İ., Kozan, B., Kaya, S., Tatar, G., & Çevik, Ö. D. (2025) · Drug Development Research · doi:10.1002/ddr.70166 · Cited by 3
“The acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), which hydrolyze ACh and BCh respectively, are the most important targets in the fight against AD (Chen et al. 2022).”
Kotochinsky, M., Mora, L., Godoi, D. C., Silva, F. A., Amorim, K. G., Amador, W. F. O., Barroso, D. C., & Fagundes, T. P. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08546-4 · Cited by 3
Bae, H. J., Kim, S.-I., Kim, S.-Y., Cho, Y. E., Sung, S., Lim, S., Cho, K., Park, S. J., & Lim, S. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1672153 · Cited by 3
Lee, J., Lee, E., Kwon, H., Moon, S., Bae, H. J., Hwang, J., Cho, G. H., Kong, H., Park, M.-H., Kim, S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209925 · Cited by 3
“In particular, the degeneration of cholinergic neurons in the basal forebrain leads to decreased acetylcholine levels in the cerebral cortex and hippocampus, contributing to deficits in learning and memory [22].”
Petrou, A., Deruvo, C., Purgatorio, R., Lichitsky, B. V., Komogortsev, A. N., Kartsev, V. G., de Candia, M., Catto, M., Altomare, C., & Geronikaki, A. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010197 · Cited by 3
“People suffering from AD have learning deficits along with an impairment of memory and language skills due to the disruption of cholinergic transmission in hippocampal areas [1].”
Din, M. M., Hayat, A., Khan, S. I., Khan, P., Gilani, M. A., Mujahid, A., Nawaz, M. H., Latif, U., & Afzal, A. (2025) · Sensors & Diagnostics · doi:10.1039/d5sd00169b · Cited by 3
Yang, Y., Atiya, A., Alrouji, M., Alshammari, M. S., Sharaf, S. E., Yadav, D. K., Alshehri, S. A., Shahwan, M. J., & Shamsi, A. (2025) · Journal of Chemistry · doi:10.1155/joch/2537269 · Cited by 3
Metadata
- Authors
- Chen, Z.-R., Huang, J.-B., Yang, S.-L., & Hong, F.-F.
- Affiliations
- Nanchang University (CN)
- Experimental Center of Pathogen Biology, Nanchang University, Nanchang 330031, China
- Corresponding author
- Yang, Shu-Long
- Hong, Fen-Fang
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-03-10
- Volume
- 27
- Issue
- 6
- Pages
- 1816
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC8949236
- OpenAlex
- W4220945110
- Cited by
- 922
- References
- 141
- Citations by year
- 2026: 256 · 2025: 347 · 2024: 202 · 2023: 87 · 2022: 29
- FWCI
- 22.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (82060661, 81660751, 81660151)
- Jiangxi Provincial Natural Science Foundation of China (20212BAB206092)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic neurotransmission, acetylcholine, cholinergic hypothesis, cognitive decline, tau phosphorylation, neuroinflammation, apoptosis, Alzheimer's disease pathogenesis, Alzheimer's disease therapeutics
- MeSH terms
- Acetylcholine, Alzheimer Disease, Humans, Signal Transduction, Cholinergic Agents, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.